Date:9/21/2009

press management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding the expected increases in the number of Ross Procedures, the expected impact of Ross Procedure advantages and evidence of long-term survival, CryoLife's belief that evidence of long-term survival is expected to grow, and growing evidence to support improved long-term survival rates for patients undergoing Ross Procedures as compared to other valve replacement options. These future events may not occur as and when expected, if at all, and are subject to various risks and uncertainties, including that additional studies may not provide the support for the advantages and long-term survival rates expected, and competitive advances, regulatory challenges, increased costs, unexpected side effects or other factors outside CryoLife's control could result in physicians' or patients' decisions not to choose the Ross Procedure. Additional risks and uncertainties impacting CryoLife's business are detailed in CryoLife's Securities and Exchange Commission filings, including CryoLife's Form 10-K filing for the year ended December 31, 2008, our Form 10-Q for the quarter ended March 31, 2009, our Form 10-Q for the quarter ended June 30, 2009, and the Company's other SEC filings. The Company does not undertake to update its forward-looking statements.

For additional information about the company, visit CryoLife's Web site: www.cryolife.com.

Reference Articles Listed Above:

Klieverik LMA, Takkenberg JJM Bekkers JA, et al. The Ross Operation: a Trojan horse? Eur Heart J 2007;28:1993-2000.

Yacoub MH, Klieverik LMA, Melina G, er al. An evaluation of the Ross Operation in adults. J Heart Valve Dis 2006;15:531-539.

'/>"/>

SOURCE CryoLife, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference
2. OpenQ Secures Investment from Leading Mid-Atlantic Venture Firm
3. ValGenesis, Inc., the Leading Provider of Validation Lifecycle Management Solutions to Regulated Life Science Companies, Today Announced Support for EMC Documentum v.6.5
4. Vestara Announces Strategic Agreement with Leading Contract Services Company Novation
5. Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study
6. Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading
7. Sigma-Aldrich Acquires ChemNavigator, Inc., to Provide Researchers With Industry-Leading Chemical Compound Selection and Procurement Services
8. One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions
9. OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd.
10. Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International
11. NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board